
Hematologist-oncologist

No OPD information available
Acute Myeloid Leukemia (AML)
Adult Immune Thrombocytopenia
Leukemia
Myelodysplastic Syndrome (MDS)
Purpura
Thrombocytopenia
Anemia
B-Cell Lymphoma
Blood Clots
Cerebral Hypoxia
Chronic Myelomonocytic Leukemia (CMML)
COVID-19
Diffuse Large B-Cell Lymphoma (DLBCL)
Disseminated Intravascular Coagulation
Hemolysis
Hemolytic Transfusion Reaction
Immune Thrombocytopenic Purpura (ITP)
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Non-Hodgkin Lymphoma
Severe Acute Respiratory Syndrome (SARS)
Shwachman-Diamond Syndrome
Splenectomy
Anoop K. Enjeti is a male doctor who helps people with different blood-related problems like leukemia, anemia, and blood clots. He also treats diseases like COVID-19 and SARS. Anoop has special skills to help patients with these conditions.
Anoop talks to his patients in a way that makes them feel comfortable and cared for. Patients trust him because he listens to their concerns and explains things clearly.
Anoop stays up-to-date with the latest medical information and research to give his patients the best care possible. This means he knows about new treatments and technologies that can help his patients.
Anoop works well with other doctors and medical professionals. He shares his knowledge and collaborates with colleagues to provide the best care for patients.
Anoop's work has helped many people live healthier lives. For example, his research on a new treatment for acute myeloid leukemia was published in a medical journal. He also led a clinical trial to test a new therapy for patients with relapsed or refractory leukemia.
In summary, Anoop K. Enjeti is a caring and knowledgeable doctor who uses his skills to help people with blood disorders and other diseases. He communicates well with patients, stays informed about the latest medical advancements, collaborates with other medical professionals, and conducts research to improve patient care. His work has had a positive impact on many lives.
Enrollment Status: Terminated
Published: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
